This paper was partially presented at the 45th Interscience Congress on Antimicrobial Agents and Chemotherapy, Washington (16–19 December 2005), oral presentation K-1811.
Incidence, Clinical Characteristics and Risk Factors of Late Infection in Solid Organ Transplant Recipients: Data from the RESITRA Study Group
Article first published online: 26 MAR 2007
American Journal of Transplantation
Volume 7, Issue 4, pages 964–971, April 2007
How to Cite
San Juan, R., Aguado, J. M., Lumbreras, C., Díaz-Pedroche, C., López-Medrano, F., Lizasoain, M., Gavalda, J., Montejo, M., Moreno, A., Gurguí, M., Torre-Cisneros, J. and RESITRA Network, Spain, (2007), Incidence, Clinical Characteristics and Risk Factors of Late Infection in Solid Organ Transplant Recipients: Data from the RESITRA Study Group. American Journal of Transplantation, 7: 964–971. doi: 10.1111/j.1600-6143.2006.01694.x
- Issue published online: 26 MAR 2007
- Article first published online: 26 MAR 2007
- Received 25 September 2006, revised 13 November 2006 and accepted for publication 28 November 2006
- Late infection;
- risk factors;
- solid organ transplantation
Information describing the incidence and clinical characteristics of late infection (LI) in solid organ transplantation (SOT) is scarce. The aim of this study was to define the incidence, clinical characteristics and risk factors for LI (>6 months) as compared with infection in the early period (<6 months) after SOT. By the online database of the Spanish Network of Infection in Transplantation (RESITRA) we prospectively analyzed 2702 SOT recipients from September 2003 to February 2005. Univariate and multivariate analysis using logistic regression were performed to calculate the risk factors associated with the development of LI. A total of 131 patients developed 176 LI episodes (8%). Global incidence of LI was 0.4 per 1000 transplant-days, ranging from 0.3/1000 in kidney transplants to 1.4 in lung transplants. Independent risk factors for LI in were: acute rejection in the early period (OR 1.5; CI 95%: 1.1–2.3), chronic graft malfunction (OR 2; CI 95%: 1.4–3), re-operation (OR 1.9; CI 95%: 1.3–2.8) relapsing viral infection apart from CMV (OR 1.9; CI 95%: 1.1–3.5), previous bacterial infection (OR 1.8; CI 95%: 1.2–2.6) and lung transplantation (OR 4.5; CI 95%: 2.6–7.8). Severe LI occurs in a subgroup of high-risk SOT recipients who deserve a more careful follow-up and could benefit from prolonged prophylactic measures similar to that performed in the early period after transplantation.